Tempest Therapeutics Files 8-K
Ticker: TPST · Form: 8-K · Filed: Oct 10, 2024 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-action, filing
TL;DR
Tempest Therapeutics filed an 8-K on Oct 7, 2024, detailing material agreements and other events.
AI Summary
On October 7, 2024, Tempest Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported other events and filed financial statements and exhibits. This filing follows a name change from Millendo Therapeutics, Inc. in 2018 and OvaScience, Inc. in 2012.
Why It Matters
This 8-K filing indicates significant corporate actions and potential changes for Tempest Therapeutics, Inc., requiring investor attention.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can impact stock price, necessitating careful review.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- Millendo Therapeutics, Inc. (company) — Former Company Name
- OvaScience, Inc. (company) — Former Company Name
- October 7, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the Material Definitive Agreement entered into by Tempest Therapeutics?
The filing indicates the entry into a Material Definitive Agreement on October 7, 2024, but the specific details of the agreement are not provided in the excerpt.
What other items are reported in this 8-K filing?
Besides the Material Definitive Agreement, the filing also reports Material Modifications to Rights of Security Holders, Other Events, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 7, 2024.
What were the former names of Tempest Therapeutics, Inc.?
Tempest Therapeutics, Inc. was formerly known as Millendo Therapeutics, Inc. (name change effective December 7, 2018) and prior to that, OvaScience, Inc. (name change effective March 8, 2012).
What is the Standard Industrial Classification for Tempest Therapeutics, Inc.?
The Standard Industrial Classification for Tempest Therapeutics, Inc. is Pharmaceutical Preparations [2834].
Filing Stats: 1,536 words · 6 min read · ~5 pages · Grade level 13.7 · Accepted 2024-10-10 07:16:01
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share TPST The Nasdaq Stock Mar
Filing Documents
- d877681d8k.htm (8-K) — 37KB
- d877681dex41.htm (EX-4.1) — 13KB
- d877681dex991.htm (EX-99.1) — 11KB
- g877681g1010033741024.jpg (GRAPHIC) — 8KB
- 0001193125-24-235598.txt ( ) — 240KB
- tpst-20241007.xsd (EX-101.SCH) — 3KB
- tpst-20241007_def.xml (EX-101.DEF) — 13KB
- tpst-20241007_lab.xml (EX-101.LAB) — 22KB
- tpst-20241007_pre.xml (EX-101.PRE) — 14KB
- d877681d8k_htm.xml (XML) — 6KB
Forward-Looking Statements
Forward-Looking Statements This report contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company's planned Phase 3 pivotal study of amezalpat (TPST-1120) in combination with atezolizumab and the timing thereof, research and development and product development plans, regulatory submissions and Roche's future supply of atezolizumab for use in one or more clinical studies conducted by the Company. The words "may," "plan," "will," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations anticipated in these forward-looking statements as a result of various factors, including risks and uncertainties relating to: unexpected safety or efficacy data; clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; unexpected litigation or other disputes; and risks described under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission ("SEC") on August 8, 2024, and other documents filed by the Company with the SEC from time to time. Any forward-looking statements contained in this report speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 4.1 Amendment No. 1, dated as of October 9, 2024, to Rights Agreement, dated as of October 10, 2023, by and between Tempest Therapeutics, Inc. and Computershare Trust Company, N.A., as rights agent. 99.1 Press Release, dated as of October 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEMPEST THERAPEUTICS, INC. Date: October 10, 2024 By: /s/ Stephen Brady Name: Stephen Brady Title: President and Chief Executive Officer